A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia-Reference-Cited by-同舟云学术

A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia

Published:2010-02 Issue:2 Volume:34 Page:254-257
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

de Lavallade Hugues,Finetti Pascal,Carbuccia Nadine,Khorashad Jamshid S.,Charbonnier Aude,Foroni Letizia,Apperley Jane F.,Vey Norbert,Bertucci François,Birnbaum Daniel,Mozziconacci Marie-Joëlle

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

2. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

3. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation;Sokal;Blood,1985

4. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers;Bertucci;Cancer Res,2006

5. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients;Frank;Leukemia,2006

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance;International Journal of Molecular Sciences;2023-09-07

2. The importance of personalized medicine in chronic myeloid leukemia management: a narrative review;Egyptian Journal of Medical Human Genetics;2023-04-06

3. The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients;Leukemia Research;2022-03

4. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers;Haematologica;2021-10-07

5. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance;Cancers;2021-09-26